Oh, now that#$%$ below the belt. You must either be short or working for a day trading operation.
I give you a thumbs down for this behavior.
But on a serious note, yes. Pfizer's single dose to cure 10 year old Crohn's was purely a biomarker level experiment, IMHO. The chances of achieving any therapeutic outcome was zero. We know this.
What is unknonw is Pfizer's motivation. My guess is that they like Mesoblast/Teva's approaches, and they want to keep a finger in the pie, but on the cheap.
Well nothing is cheaper than a company with a failed one trick pony stroke trial.
This is the harsh reality. But also a reality is that little guys like us are like ants on a sugar cube, dreaming big without knowing the sugar cube is on a busy freeway of fast moving luxury cars driven by people who already have what we want. Eat, drink, and be merry for tomorrow the results come in.
If they like what they see, we need the backstop to bad stroke data.
As it looks now, Pfizer is holding this card.
Obviously the Crohn's trial was designed to provide research data...with clinical success from a single dose of 10 years Crohn's being a remote afterthought.
Chugai is gambling nothing.
They can use MultiStem for GvHD and cover their losses if the stroke trial fails.
Meanwhile retailers suckered in by the mirage of $10 million in confidence could lose everything in addition to spiking the price for the warrants.
Did Gil say we have 50% institutional ownership? What else did he say....
Chugai holds all the Multistem cards in Japan.
Their agreement with Athersys does not end with stroke but includes all therapeutic indications for Multistem.
For just $10 million, Chugai bets on stroke and simultaneously gets a GvHD insurance policy to cover all losses in the event of stroke trial failure.
Fore shareholders though, GvHD will not be enough to right the ship. If the stroke trial fails, Athersys will rapidly sink to the bottom of the north Atlantic.
It will then be salvaged for scrap by Pfizer with golden parachutes for management.
But, if the Athersys stroke trial is a success...all will be right in the world...but when does this ever happen?
JCR Pharmaceuticals is focusing on the commercialization of Prochymal in Japan for the treatment of patients with GvHD. Chugai could be giving chase, knowing the 10 million could be returned over time for GvHD. With this in mind, the gamble is not quite that big for Chugai. The stroke results are still a big unknown, but in the event of success, would you not predict a PCYC scenario playing out with the likes of JNJ or Pfizer? If MAPC is that potent, then the sky is the limit.
Twitter, yes, that is what Gil was doing while having his coffee.
Athersys Inc athersys
Athersys and Chugai Enter License Agreement & Collaboration to Develop MultiStem® Therapy for Stroke in Japan
about an hour ago
I think you are right. More details from Athersys tomorrow.
Everyone will be sleeping easy except for the shorts!
Something tells me the press release coordination was lost in translation.
Somebody needs to call Gil and let him know that the party is on early.
Athersys website went to bed early....
Osiris Receives Milestone Payment for Prochymal Development Progress in
COLUMBIA, Md. -- April 28, 2010
Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that it has achieved
a $1 million milestone payment from its Japanese commercial partner, JCR
Pharmaceuticals, for development progress made advancing Prochymal for the
treatment of acute graft vs. host disease (GvHD) in Japan.
In 2003, Osiris formed a partnership with JCR Pharmaceuticals focusing on the
commercialization of Prochymal in Japan for the treatment of patients with
GvHD. The collaboration provides for additional milestone payments for
regulatory and sales milestones, as well as significant royalty payments on
sales of the drug in Japan.
Chugai just paid $10 million on speculation.
How will ATHX be worth $20 PPS tomorrow.
Until the results come in, we move sideways.
Still no Athersys press release on their website?
Does ATHX still own the USA stroke market?
Culturing protocols for human multipotent adult stem cells.
Culture procedures are presented that support the initiation and controlled expansion of the multipotent adult progenitor cell (MAPC) population within the human bone marrow derived multipotent mesenchymal stromal cell compartment. Culture procedures or conditions and characterization assays that maintain and survey the distinctive primitive MAPC properties are discussed in the context of cell culturing platforms that facilitate controlled expansion of clinical grade human MAPC product to levels required for mid to late stage clinical testing.
Methods Mol Biol (2015) 1235:49-58